Risk factors influencing the outcome of peptic ulcer bleeding in end stage renal diseases after initial endoscopic haemostasis

International Journal of Clinical Practice

Volumn 66, Issue 8, 2012, Pages 774-781

  Lin, S C ^a   Wu, K L ^a   Chiu, K W ^a   Lee, C T ^a   Chiu, Y C ^a   Chou, Y P ^a   Hu, M L ^a   Tai, W C ^a   Chiou, S S ^a   Hu, T H ^a   Changchien, C S ^a   Chuah, S K ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BLOOD TRANSFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEMODIALYSIS; HEMOSTASIS; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TERTIARY HEALTH CARE; THROMBOCYTE COUNT; TIME;

EID: 84863989640     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02974.x     Document Type: Article

References (34)

1. United States Renal Data System, Annual Data Report 2011. Available at. Last assessed date May 26th, 2012
2. Milito G, Taccone-Gallucci M, Brancaleone C, et al., The gastrointestinal tract in uremic patients on long-term hemodialysis. Kidney Int 1985; 28 (Suppl. 17): S157-60.
3. Andrulli A, Malfi B, Recchia S, Ponti F, Triolo G, Segoloni G,. Patients with chronic renal failure are not at a risk of developing chronic peptic ulcers. Clin Nephrol 1985; 23: 245-8. (Pubitemid 15036394)
4. Ala-Kaila K,. Upper gastrointestinal findings in chronic renal failure. Scand J Gastroenterol 1987; 22: 372-6. (Pubitemid 17054313)
5. Wee A, Kang JY, Ho MS, Choong HL, Wu AY, Sutherland IH,. Gastroduodenal mucosa in uraemia: endoscopic and histological correlation and prevalence of Helicobacter-like organisms. Gut 1990; 31: 1093-6. (Pubitemid 20343046)
6. Kang JY, Ho KY, Yeoh KG, et al., Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection. J Gastroenterol Hepatol 1999; 14: 771-8. (Pubitemid 29426409)
7. Chalasani N, Cotsonis G, Wilcox CM,. Upper gastrointestinal bleeding in patients with chronic renal failure: role of vascular ectasia. Am J Gastroentero 1996; 91: 2329-32. (Pubitemid 26383195)
8. Silvertstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J,. The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors. Gastrointest Endosc 1981; 27: 80-93. (Pubitemid 11105364)
9. Branicki FJ, Boey J, Fok PJ, et al., Bleeding duodenal ulcer. A prospective evaluation of risk factors for rebleeding and death. Ann Surg 1990; 211: 411-8. (Pubitemid 20138181)
10. Rockall TA, Logan RF, Devlin HB, Northfield TC,. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316-21. (Pubitemid 26074312)
11. Barkun AN, Bardou M, Kuipers EJ, et al., International Consensus Upper Gastrointestinal Bleeding Conference Group: International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152: 101-3.
12. Cheung J, Yu A, LaBossiere J, Zhu Q, Fedorak RN,. Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. Gastrointest Endosc 2010; 71: 44-9.
13. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-266.
14. Xu WH, Wang JH, Tsai MS, et al., The effects of cefazolin on cirrhotic patients with acute variceal hemorrhage after endoscopic interventions. Surg Endosc 2011; 25: 2911-8.
15. Hu ML, Wu KL, Chiu KW, et al., Predictors of rebleeding after initial hemostasis with epinephrine injection in high-risk ulcers. World J Gastroenterol 2010; 16: 5490-5.
16. Toke AB,. GI bleeding risk in patients undergoing dialysis. Gastrointest Endosc 2010; 71: 50-2.
17. Boccardo P, Remuzzi G, Galbursera M,. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579-89. (Pubitemid 39426390)
18. Galbusera M, Remuzzi G, Boccardo P,. Treatment of bleeding in dialysis patients. Semin Dial 2009; 22: 279-86.
19. Sreedhara R, Itagaki I, Lynn B, Hakim RM,. Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 1995; 25: 555-63.
20. Remuzzi G, Benigni A, Dodesini P, et al., Platelet function in patients on maintenance hemodialysis: depressed or enhanced? Clin Nephrol 1982; 17: 60-3. (Pubitemid 12168761)
21. Remuzzi G, Livio E, Marchiaro G,. Altered platelet function in chronic uraemia only partially corrected by hemodialysis. Nephron 1987; 22: 347-53.
22. Pepper RJ, Gale DP, Wajed J, et al., Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodial Int 2007; 11: 430-4. (Pubitemid 47534868)
23. Yang CC, Shin JS, Lin XZ, Hsu PI, Chen KW, Lin CY,. The natural history (fading time) of stigmata of recent hemorrhage in peptic ulcer disease. Gastrointest Endosc 1994; 40: 562-6.
24. Lin HJ, Perng CL, Lee YL, Lee CH, Lee SD,. Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: a prospective study. Gut 1994; 35: 1389-93.
25. Cheng HC, Sheu BS,. Intravenous proton pump inhibitors for peptic ulcer bleeding: clinical benefits and limits. World J Gastrointest Endosc 2011; 3: 49-56.
26. Cheng HC, Chang WL, Yeh YC, Chen WY, Tsai YC, Sheu BS,. Seven-day intravenous low-dose omeprazole infusion reduces peptic ulcer rebleeding for patients with comorbidities. Gastrointest Endosc 2009; 70: 433-9.
27. Tseng GY, Fang CT, Lin HJ, Yang HB, Tseng GC, Wang PC,. Efficacy of an intravenous proton pump inhibitor after endoscopic therapy with epinephrine injection for peptic ulcer bleeding in patients with uraemia: a case-control study. Aliment Pharmacol Ther 2009; 30: 406-13.
28. Kang JM, Kim N, Lee DH, et al., Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol 2008; 23: 1287-91.
29. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T,. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
30. Lim PW, Goh KL, Wong BC,. CYP2C19 genotype and the PPIs-focus on rabeprazole. J Gastroenterol Hepatol 2005; 20 (Suppl): S22-8. (Pubitemid 44933475)
31. Oh JH, Choi MG, Dong MS, et al., Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients. J Gastroenterol Hepatol 2007; 22: 1429-34.
32. Andriulli A, Loperfido S, Focareta R, et al., High-versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol 2008; 103: 3011-8.
33. Cheng HC, Kao AW, Chuang CH, Sheu BS,. The efficacy of high- and low-dose intravenous omeprazole in preventing rebleeding for patients with bleeding peptic ulcers and comorbid illnesses. Dig Dis Sci 2005; 50: 1194-201.
34. Simon-Rudler M, Massard J, Bernard-Chabert B, et al., Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study. Aliment Pharmacol Ther 2007; 25: 949-54. (Pubitemid 46525350)